Part 2: Patient Affordability After the IRA: Potential Impacts
The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.
On-Demand: Cell & Gene Day, 2023
Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges? Find out at Cell & Gene Day 2023, a free virtual event, streaming on demand HERE.
Precision Value & Health Acquires Makara Health, Expanding the Company’s Footprint and Communications Capabilities in Europe
Bethesda, Md., April 12, 2023 — Precision Value & Health, the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, today announced that it has acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions.
With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.
Part 1: The Growing Emergence of Biosimilars
Biosimilars are on track to reduce drug costs by $100 billion—but not everyone is on board. The Inflation Reduction Act has provisions that encourage their uptake. Get the details from PRECISIONvalue expert Amy Martin in this free brief (part 1 of 5).
In Healthcare? What you Need to Know about ESG and Proxy Voting
From large institutional investors to smaller quantitative investors, proxy voting guidelines increasingly reference ESG issues such as board diversity and climate change, requiring companies to meet a minimum ESG performance threshold for investors to vote in accord with management.
In this latest edition of Stern IR’s “ESG In Focus” series, we leverage proprietary data on a large number of investors in the healthcare and biotech space to assess their level of engagement around ESG and how ESG factors into their approach to proxy voting.
Article: The Future of Gene Therapies: Three Trends
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.
Article: The Promise and Peril of ChatGPT in Healthcare and Pharma Marketing
Since its release on November 30, 2022, ChatGPT has generated buzz across all corners of the internet and within every industry. The technology is likely to have in impact in healthcare, the life sciences, and marketing. Precision’s Marty Samples and others weigh in on its uses in healthcare and the life sciences, including its potential and potential pitfalls.
Conference: Meeting on the Med, 2023
Precision will be at this year’s Meeting on the Med, April 12-14, 2023, in Barcelona, Spain. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for cell and gene therapies.
Connect with our Advanced Therapy experts
- Visit us through any of the numerous networking opportunities at Meeting on the Med 23′
- Be sure to attend the ADVANCE sponsored workshop on April 12, 2023, at 4:45PM – 5:30PM CET |Location: Hotel Arts Barcelona (BioCentriq Ballroom: Gaudi 3)
You can register for Meeting on the Med below:
Article: The FDA and AAV-Based Gene Therapy Safety: What You Should Know
Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.
CLICK HERE to read the full article
Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair
BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”
